Sanara Medtech Inc (SMTI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sanara Medtech Inc (SMTI) has a cash flow conversion efficiency ratio of 0.665x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.95 Million) by net assets ($5.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sanara Medtech Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Sanara Medtech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SMTI current and long-term liabilities for a breakdown of total debt and financial obligations.
Sanara Medtech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sanara Medtech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HyVision System. Inc
KQ:126700
|
-0.033x |
|
Intelligent Monitoring Group Ltd
AU:IMB
|
0.149x |
|
Kimia Farma Persero Tbk
JK:KAEF
|
0.018x |
|
Shriram Properties Limited
NSE:SHRIRAMPPS
|
0.003x |
|
Orion Minerals Ltd
AU:ORN
|
-0.059x |
|
Antony Waste Handling Cell Limited
NSE:AWHCL
|
0.035x |
|
Groupe Sfpi
PA:SFPI
|
0.026x |
|
Surya Fajar Capital Tbk PT
JK:SFAN
|
0.016x |
Annual Cash Flow Conversion Efficiency for Sanara Medtech Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Sanara Medtech Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Sanara Medtech Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.93 Million | $6.79 Million | 1.145x | +187346.65% |
| 2024-12-31 | $38.91 Million | $-23.78K | -0.001x | +99.16% |
| 2023-12-31 | $44.59 Million | $-3.25 Million | -0.073x | +45.33% |
| 2022-12-31 | $41.72 Million | $-5.55 Million | -0.133x | +16.61% |
| 2021-12-31 | $30.15 Million | $-4.81 Million | -0.160x | +76.89% |
| 2020-12-31 | $5.84 Million | $-4.03 Million | -0.691x | -103.74% |
| 2019-12-31 | $6.39 Million | $-2.17 Million | -0.339x | -236.05% |
| 2018-12-31 | $1.11 Million | $277.14K | 0.249x | +118.27% |
| 2017-12-31 | $102.54K | $-139.86K | -1.364x | -41.01% |
| 2016-12-31 | $-423.07K | $409.25K | -0.967x | -202.23% |
| 2015-12-31 | $-1.27 Million | $-1.20 Million | 0.946x | -53.70% |
| 2014-12-31 | $-825.40K | $-1.69 Million | 2.043x | +176.87% |
| 2013-12-31 | $-2.47 Million | $-1.82 Million | 0.738x | +129.08% |
| 2012-12-31 | $-3.81 Million | $-1.23 Million | 0.322x | +261.94% |
| 2011-12-31 | $-3.86 Million | $-343.60K | 0.089x | +117.11% |
| 2010-12-31 | $2.87 Million | $-1.49 Million | -0.520x | +7.01% |
| 2009-12-31 | $2.31 Million | $-1.30 Million | -0.560x | -116.99% |
| 2008-12-31 | $-321.26K | $-1.06 Million | 3.295x | +1468.87% |
| 2007-12-31 | $-1.81 Million | $-380.90K | 0.210x | -33.10% |
| 2006-12-31 | $-1.27 Million | $-398.97K | 0.314x | -67.45% |
| 2005-12-31 | $-647.47K | $-624.45K | 0.964x | +107.24% |
| 2004-12-31 | $41.20K | $-548.46K | -13.313x | -3955.33% |
| 2001-12-31 | $-2.10 Million | $-723.86K | 0.345x | -16.37% |
| 2000-12-31 | $-1.38 Million | $-569.36K | 0.413x | -75.18% |
| 1999-12-31 | $-377.38K | $-627.86K | 1.664x | -- |
About Sanara Medtech Inc
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and seco… Read more